32. Myelodysplasia

  1. Alan J. Sinclair2,3,
  2. Dr John E. Morley4 and
  3. Professor Bruno Vellas5
  1. Martha Wadleigh,
  2. David S. Rosenthal and
  3. Richard M. Stone

Published Online: 12 MAR 2012

DOI: 10.1002/9781119952930.ch32

Pathy's Principles and Practice of Geriatric Medicine, Volume 1 & 2, Fifth Edition

Pathy's Principles and Practice of Geriatric Medicine, Volume 1 & 2, Fifth Edition

How to Cite

Wadleigh, M., Rosenthal, D. S. and Stone, R. M. (2012) Myelodysplasia, in Pathy's Principles and Practice of Geriatric Medicine, Volume 1 & 2, Fifth Edition (eds A. J. Sinclair, J. E. Morley and B. Vellas), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781119952930.ch32

Editor Information

  1. 2

    Bedfordshire & Hertfordshire Postgraduate Medical School, University of Bedfordshire, Luton, UK

  2. 3

    Institute of Diabetes for Older People (IDOP), Luton, UK

  3. 4

    Saint Louis University School of Medicine and St Louis Veterans' Affairs Medical Center, St Louis, MO, USA

  4. 5

    Gérontopôle, Toulouse University Hospital and INSERM Unit 558, University of Toulouse III, Toulouse, France

Author Information

  1. Harvard Medical School, Boston, MA, USA

Publication History

  1. Published Online: 12 MAR 2012
  2. Published Print: 13 APR 2012

ISBN Information

Print ISBN: 9780470683934

Online ISBN: 9781119952930

SEARCH

Keywords:

  • myelodysplastic syndromes; erythropoietin stimulating agents;
  • lenalidomide;
  • 5-azacitidine;
  • decitabine

Summary

The myelodysplastic syndromes (MDS) represent a group of clonal stem cell disorders with a varied spectrum of presentation. Prominent features include one or more cytopenias, dysplasia in the bone marrow and the potential to evolve into acute myeloid leukaemia. MDS is a disease of older patients and treatment strategies are divided into higher and lower intensity therapy. The choice of therapy takes into account many variables, including patient age, comorbidity, functional status and risk of underlying disease. Over the past decade, three agents have been approved by the FDA for the treatment of MDS. This chapter discusses the diagnosis, classification and current treatment options available for patients with myelodysplasia.